LOXO ONCOLOGY, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.loxooncology.com
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05023980
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Centro Gaucho Integrado - Mae de Deus Center, Porto Alegre, Rio Grande Do Sul, Brazil
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT04965493
- Locations
- 🇺🇸
The James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT04819100
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸GenesisCare, Aventura, Florida, United States
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04782076
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04666038
- Locations
- 🇨🇦
Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇨🇳Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04662255
- Locations
- 🇺🇸
Mercy Health-Paducah Medical Oncology and Hematology, Paducah, Kentucky, United States
🇺🇸Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Conditions
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04280081
- Locations
- 🇨🇳
The First Affiated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04211337
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 261
- Registration Number
- NCT04194944
- Locations
- 🇨🇳
The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China
🇦🇷Alexander Fleming, Ciudad de Buenos Aires, Argentina
🇨🇳Buddhist Dalin Tzu Chi General Hospital, Dalin Town, Chiayi, Taiwan
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT03906331
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States